Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$87.2 - $114.05 $470,880 - $615,870
-5,400 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$94.19 - $124.49 $169,542 - $224,082
1,800 Added 50.0%
5,400 $599,000
Q4 2021

Feb 14, 2022

SELL
$119.57 - $139.07 $789,162 - $917,862
-6,600 Reduced 64.71%
3,600 $461,000
Q3 2021

Nov 15, 2021

BUY
$109.17 - $142.35 $1.11 Million - $1.45 Million
10,200 New
10,200 $1.36 Million
Q3 2020

Nov 16, 2020

SELL
$72.74 - $92.5 $436,439 - $555,000
-6,000 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$48.02 - $79.04 $288,120 - $474,240
6,000 New
6,000 $440,000
Q4 2019

Feb 14, 2020

SELL
$47.06 - $56.64 $701,194 - $843,936
-14,900 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$47.45 - $58.05 $707,005 - $864,945
14,900 New
14,900 $710,000
Q2 2019

Aug 14, 2019

SELL
$39.26 - $54.21 $1.5 Million - $2.07 Million
-38,141 Closed
0 $0
Q1 2019

May 15, 2019

SELL
$29.84 - $43.92 $3.24 Million - $4.77 Million
-108,700 Reduced 74.03%
38,141 $1.55 Million
Q4 2018

Feb 14, 2019

SELL
$29.95 - $46.34 $919,405 - $1.42 Million
-30,698 Reduced 17.29%
146,841 $4.58 Million
Q3 2018

Nov 14, 2018

BUY
$40.12 - $45.55 $6.87 Million - $7.8 Million
171,300 Added 2745.63%
177,539 $8.09 Million
Q2 2018

Aug 14, 2018

SELL
$38.72 - $42.52 $1.17 Million - $1.28 Million
-30,100 Reduced 82.83%
6,239 $261,000
Q1 2018

May 15, 2018

SELL
$39.4 - $47.39 $21.2 Million - $25.5 Million
-538,512 Reduced 93.68%
36,339 $1.49 Million
Q4 2017

Feb 14, 2018

SELL
$37.27 - $43.02 $3.12 Million - $3.6 Million
-83,688 Reduced 12.71%
574,851 $23.6 Million
Q3 2017

Nov 14, 2017

BUY
$33.75 - $41.67 $22.2 Million - $27.4 Million
658,539
658,539 $26.3 Million

Others Institutions Holding CTLT

About Catalent, Inc.


  • Ticker CTLT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 179,896,000
  • Market Cap $10.1B
  • Description
  • Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...
More about CTLT
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.